-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We maintain our Sell rating and our target price of CAD130. The target of CAD130 reflects our unchanged 2027 P/E multiple of 60x, still a premium to CCO's one- and three-year averages of 57.2x and 39.3x, respectively. We believe CCO's premium valuation is warranted for various reasons but overdone. Strong support for nuclear projects and energy needs have supported spot pricing in uranium, but plant build-outs carry considerable timing and cost risks. Q1 earnings provided a modest beat on top and bottom lines. However, given the valuation, the lack of guidance boost and incremental good news kept the story at its status quo. The story is well understood by the market, and we feel the name is tethered to energy/AI sentiment and developments, which may be volatile in the near term. We lower our 2026 EPS estimate by CAD0.15 to CAD1.56 and maintain our 2027 EPS at CAD2.17.